このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Protalix BioTherapeutics 将来の成長

Future 基準チェック /56

Protalix BioTherapeuticsは、83.9%と43.2%でそれぞれ年率83.9%で利益と収益が成長すると予測される一方、EPSはgrowで80.4%年率。

主要情報

83.9%

収益成長率

80.4%

EPS成長率

Biotechs 収益成長	30.6%
収益成長率	43.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 May 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:PBDA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	167	100	N/A	N/A	1
12/31/2025	101	55	N/A	N/A	1
12/31/2024	53	9	N/A	N/A	1
3/31/2024	60	7	4	6	N/A
12/31/2023	65	8	-2	-1	N/A
9/30/2023	64	11	-9	-8	N/A
6/30/2023	67	9	-11	-10	N/A
3/31/2023	41	-16	-23	-22	N/A
12/31/2022	48	-15	-26	-25	N/A
9/30/2022	48	-18	-28	-27	N/A
6/30/2022	45	-18	-21	-20	N/A
3/31/2022	43	-24	-8	-6	N/A
12/31/2021	38	-28	-12	-10	N/A
9/30/2021	49	-21	-14	-13	N/A
6/30/2021	48	-21	-16	-14	N/A
3/31/2021	53	-14	-30	-29	N/A
12/31/2020	63	-7	-27	-26	N/A
9/30/2020	61	-7	-23	-22	N/A
6/30/2020	65	-6	-23	-22	N/A
3/31/2020	66	-9	-20	-19	N/A
12/31/2019	55	-18	-20	-19	N/A
9/30/2019	47	-24	-20	-20	N/A
6/30/2019	45	-26	-3	-3	N/A
3/31/2019	38	-26	-6	-6	N/A
12/31/2018	34	-26	-8	-8	N/A
9/30/2018	28	-34	13	14	N/A
6/30/2018	23	-40	-11	-10	N/A
3/31/2018	25	-32	-12	-11	N/A
12/31/2017	21	-83	N/A	-10	N/A
9/30/2017	19	-73	N/A	-35	N/A
6/30/2017	16	-69	N/A	-28	N/A
3/31/2017	11	-80	N/A	-31	N/A
12/31/2016	9	-29	N/A	-32	N/A
9/30/2016	7	-35	N/A	-29	N/A
6/30/2016	4	-34	N/A	-34	N/A
3/31/2016	3	-29	N/A	-27	N/A
12/31/2015	4	-27	N/A	-24	N/A
9/30/2015	-6	-31	N/A	-25	N/A
6/30/2015	-4	-33	N/A	-26	N/A
3/31/2015	-2	-32	N/A	-27	N/A
12/31/2014	4	-33	N/A	-29	N/A
9/30/2014	15	-32	N/A	-29	N/A
6/30/2014	15	-30	N/A	-28	N/A
3/31/2014	15	-31	N/A	-29	N/A
12/31/2013	N/A	-35	N/A	-31	N/A
9/30/2013	10	-27	N/A	-24	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PBDAの予測収益成長率 (年間83.9% ) は貯蓄率 ( 0.7% ) を上回っています。

収益対市場: PBDAの収益 ( 83.9% ) はGerman市場 ( 18.5% ) よりも速いペースで成長すると予測されています。

高成長収益: PBDAの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: PBDAの収益 ( 43.2% ) German市場 ( 5.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: PBDAの収益 ( 43.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PBDAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Protalix BioTherapeutics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Forecast breakeven pushed back to 2022

Recent updates

Protalix BioTherapeutics, Inc. to Report Q1, 2024 Results on May 10, 2024

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 27, 2024

Protalix BioTherapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Protalix BioTherapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023

Protalix BioTherapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 28, 2023

Chiesi Global Rare Diseases and Protalix Biotherapeutics, Inc. Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

Protalix Biotherapeutics, Inc. and Chiesi Global Rare Diseases Announces European Commission Grants Marketing Authorization to PRX-102 (Pegunigalsidase Alfa) for the Treatment of Adult Patients with Fabry Disease

Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Third quarter 2022 earnings released: US$0.072 loss per share (vs US$0.092 loss in 3Q 2021)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.25 loss in 2Q 2021)

Protalix BioTherapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee

First quarter 2022 earnings released: US$0.05 loss per share (vs US$0.14 loss in 1Q 2021)

Protalix BioTherapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

President recently bought €94k worth of stock

Protalix Biotherapeutics, Inc. Announces Topline Results from BALANCE Pivotal Phase III Clinical Trial Evaluating pegunigalsidase alfa

Full year 2021 earnings released: US$0.63 loss per share (vs US$0.22 loss in FY 2020)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Submission of Marketing Authorization Application to the European Medicines Agency for PRX-102 for Treatment of Fabry Disease

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.13 loss in 2Q 2020)

Protalix BioTherapeutics, Inc. Announces Submission of Type A Meeting Request to the FDA

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease

Forecast breakeven pushed back to 2022

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.096 profit in 1Q 2020)

Protalix Biotherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from Fda

Full year 2020 earnings released: US$0.22 loss per share (vs US$1.23 loss in FY 2019)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Positive Topline Results from Bright Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 Mg/Kg Every Four Weeks for Treatment of Fabry Disease

Protalix Biotherapeutics Enters into an Exclusive Partnership with Sarcomed USA to Develop Alidornase Alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

New 90-day high: €3.74

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

New 90-day high: €3.44

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Results of Bridge Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announces Extension of Pdufa Date for Pegunigalsidase Alfa for the Propose Treatment of Fabry Disease

Third quarter earnings released

New 90-day low: €2.76

Chiesi Farmaceutici S.P.A. and Protalix BioTherapeutics, Inc Announce Launch of an Expanded Access Program (Eap) in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Protalix Biotherapeutics and Chiesi Farmaceutici Announce Successful Pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase Alfa for the Treatment of Fabry Disease in the United States

New 90-day low - €2.82

Protalix Biotherapeutics Regains Compliance with NYSE American Continued Listing Standards

New 90-day low - €2.88

First half earnings released

Protalix BioTherapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘